The firm is developing an electrochemical sensor platform to detect sepsis and other conditions using a single drop of blood and a single-use cartridge.
Stanford researchers showed that wearables could identify inflammation, insulin resistance, and the onset of infection.
The firm said that it will manufacture assays for its next-generation immunoassay and clinical chemistry system at an expanded facility.
T2 said it's in a strong position to achieve planned portfolio milestones over the next two years, including submitting its next test for FDA clearance next year.
The test is based on a biomarker signature that consists of a core set of 31 genes associated with endotoxin tolerance in sepsis patients.
The developer has presented clinical results that provide a base for completing development of a multi-protein test kit and conducting a clinical trial in advance of FDA submission.
The Centre for Drug Research and Development has spun out the company to develop a rapid detection test based on the body's immune response.
Executives of firms developing and launching various assays believe their diagnostic tests will be among the most important tools in controlling Zika.
Researchers from the diagnostics company will work with researchers from the microbial genomics lab of George Weinstock.
The company is also developing a next-generation sequencing product that may be applied at the point of need to test for bloodstream infections and later as a liquid biopsy for cancer.